Table 2. Management and outcomes of AML.
| Treatment protocols | N (%) | CR N (%) |
Relapse N (%) | Relapse therapy N (%) |
Second CR N (%) |
|---|---|---|---|---|---|
| Induction therapy with “7 + 3” | 77 (32%) | 42 (55%) | 32 (76%) | 20 (65%) | 2 (10%) |
| Consolidation therapy with HiDAC (after reaching CR with “7 + 3”) | 12 (29%) | 9 (75%) | 7 (78%) | 2 (29%) | |
| Consolidation therapy with “7 + 3” followed with maintenance therapy with “5 + 5” (after reaching CR with “7 + 3”) | 30 (71%) | 23 (77%) | 13 (59%) | 3 (23%) | |
| LDAC | 15 (6%) | 5 (33%) | 4 (80%) | N/A | 0 |
| Other | 16 (21%) | N/A | N/A | N/A | N/A |